Latham & Watkins Advised on Liquidia Corporation’s Common Stock Financing

Liquidia Corporation (NASDAQ: LQDA) (the Company or Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, has announced the pricing of an underwritten public offering and a concurrent private placement, with anticipated total gross proceeds of approximately US$67.5 million, before deducting underwriting discounts and commissions, and expenses.

The Company offered 6,460,674 shares of common stock in the public offering at a price of US$8.90 per share. In addition, Liquidia entered into a common stock purchase agreement with funds managed by Caligan Partners LP for the sale of 1,123,595 shares of common stock at a purchase price of US$8.90 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended. The public offering and concurrent private placement are expected to close on September 12, 2024, subject to customary closing conditions.

Latham & Watkins is advising the underwriters in the offering, with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Katie Lovejoy and Sabrina Singh. Advice was also provided on IP matters by Chicago/New York partner Marc Zubick, with associate Alex Grabowski; and on FDA matters by Washington, D.C. partner Elizabeth Richards, with associate Meryl Bartlett.